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1. Introduction 
Nanotechnology has shown tremendous promise in target-specific delivery of drugs in the 
body. Although passive and active targeted-drug delivery has addressed a number of 
important issues, additional properties that can be included in nanocarrier systems to 
enhance the bioavailability of drugs at the disease site, and especially upon cellular 
internalization, are very important.  
Upon the support of nanotechnology, scientists in hybrid research field could deal with the 
combination of different substances from macroscopic to molecular level, and create novel 
materials with intentional functionalities. Thus, the hybridization technology can be 
adapted to create efficient drug nanocarriers. Hybridized drug-carriers can be made from a 
variety of organic and inorganic materials including biodegradable polymers and inorganic 
clays. The selection of material for development of nanoparticle carriers is mainly dictated 
by the desired diagnostic or therapeutic goal, type of payload, material safety profile, and 
the route of administration. 
Among the various approaches for exploiting developments in drug nanotechnology, 
layered double hydroxide (LDH) materials offer some unique advantages, as their medical 
properties support their different pharmaceutical applications. By the introduction of drug-
LDH nanocomposite platform, the delivery system becomes an active participant rather 
than passive vehicle in the optimization of drug-therapy. 
In this chapter, we are going to focus on the intercalation chemistry of LDH, the different 
LDH nanocomposites formulation strategies, and the physical and chemical properties of 
drug-LDH nanocomposites. In addition, we discuss the different drug-LDH pharmaceutical 
applications such as drug solubility, dissolution behavior, and the delivery of some non-
steroidal anti-inflammatory drugs (NSAIDs) to its active target-sites. 
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2. Layered double hydroxides (LDHs) 
Driven by the high promise for new nanotechnological applications and our belief that 
development of biomedical science demands new advanced materials, clays are of particular 
interest. An interesting category of clay materials is (LDHs). 
2.1 Structure of LDHs 
LDHs are a family of natural and synthetic compounds having a general formula of [MII1-
xMIIIx(OH)2](Yn-)x/n·yH2O, where MII and MIII represent divalent and trivalent metal ions 
respectively, and Yn- is the anion between the layers. MII can be for example Mg2+, Ca2+, 
Zn2+, Co2+, Cu2+; and MIII can be Al3+, Cr3+, Co3+, Fe3+, Mn3+. The interlayer anion Yn- can be 
Cl-, NO3-, CO32-, or organic anions (Boclair et al., 1999). LDHs are also known as hydrotalcite-
like compounds due to their structural similarities to hydrotalcite mineral, or known as 
anionic clays. They consist structurally of brucite-like sheet with hexagonal-shaped 
crystallite layers as shown in the scanning electron micrograph (SEM) of Figure 1. This 
structured-shape is formed by the edge sharing of [Mg(OH)6] octahedral as displayed in the 
schematic illustration of Figure 2. The net positive charge of LDH is due to a partial 
substitution of M2+ by M3+; typically, the substitution leads to values of x in the range of 0.2 
to 0.33. This positive charge is effectively dispersed uniformly across each layer (Rives, 
2002). Anions are attracted into the interlayer space along with water molecules, balancing 
the overall positive charge with a negative one of equal magnitude. LDH materials appear 
in nature and can be readily prepared in the laboratory. In nature, they are formed from the 
weathering of basalts (Bail et al., 1987) or precipitation in saline water sources (Frost & 
Erickson, 2004). All natural LDH minerals have a structure similar to hydrotalcite, which 
has the formula [Mg6Al2(OH)16]·CO3·4H2O (Cavani et al., 1991). Unlike clays, however, 
layered double hydroxides are not discovered in large scale.  
2.2 Preparation techniques of LDHs 
LDH can be prepared in the laboratory by different techniques. Coprecipitation (Miyata, 
1980), anion exchange (Liu et al., 2006), glycerol-effected exchange (Carlino, 1997), 
reconstruction (Geraud et al., 2007) and homogeneous precipitation (Ogawa & Kaiho, 2002). 
Coprecipitation is perhaps the most widely used technique of LDH. In this method, LDH is 
precipitated by adding a base to a stirred aqueous solution containing the metals salts (MII 
and MIII) and the desired anion. A 50 wt% solution of alkali hydroxide was found to be 
effective in the precipitation of pure LDH materials without impurities at the pH range 8.0-
10.0. LDH systems generally prefer carbonate to most other anions. Thus, carbonate and 
carbon dioxide must be rigorously excluded from the medium in case of anions other than 
carbonate. The metal hydroxide layers nucleate and grow under stirring. Aging of the 
formed LDH precipitate is preferable to improve the crystallinity of LDH materials which is 
considered as an effective property in the stabilization of the beneficial intercalated anions. 
The aging process of LDH is often used as a post-treatment method and it usually 
performed by hydrothermal or microwave treatment techniques (Miyata, 1980). 
2.3 Identification of LDHs and their nanocomposites 
LDHs can be identified by different techniques: Powder X-ray diffraction (PXRD) is a very 
useful tool to analyze the crystalline structure, lattice parameters, crystal morphology, and 
crystal size of LDHs. This application is based on the fact that an X- ray diffraction is unique 
for each crystalline substance. The reflections of LDH are indexed to a hexagonal lattice 
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(Zou et al., 2007) with rhombohedral 3R symmetry. The peaks of LDH from the lower angle 
to the high angle are the diffraction by planes (003), (006), (009), etc. Thus, the cell parameter 
c (the thickness of one layer consisting of a brucite-like sheet and one interlayer) of LDH is 
usually estimated as 3d003 or d003 + 2d006 + 3d009, and the cell parameter a (the mean closest 
metal-metal distance within a layer) can be easily calculated from the 110 reflection (a = 
2d110). XRD measurement is based on Bragg’s law: nǌ = 2d sin θ, where ǌ is the wavelength 
 
 
Fig. 1. SEM image of a hexagonal-shaped crystallite layer of Mg-Al LDH 
 
Fig. 2a. Schematic illustration of the brucite-like sheet structure of LDH; Horizontal view 
with a layer thickness of 4.8Å. 
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Fig. 2b. Schematic illustration of the brucite-like sheet structure of LDH; Vertical view. 
of the incident X-ray beam, d is the spacing between each lattice, θ is the angle between the 
incident X-ray beam and the reflecting crystal plan, and n is an integer representing the 
order of the reflection (in practice, taken to be 1). Fourier transform infrared spectroscopy 
(FTIR): FTIR has been used as a tool for the evaluation of a molecule’s structure by studying 
the vibration change occurring from the excitation of the bonds. In LDH, FTIR is used to 
determine the presence or absence of particular active agents in the interlayer, and to check 
that LDH layer material matches the expected spectrum. Since functional groups absorb at 
characteristic frequencies of infrared radiation, many compounds can be identified using 
only their spectra. Higher-quality scans of FTIR can be performed to give detailed 
information about the interlayer environment, to indicate the presence or absence of key 
functional groups in the system, to illustrate the relative orderliness of the hydroxide layers, 
and to determine the extent of ordering of water in the sample. We can also use FTIR to 
determine how much contamination (e.g. how much carbonate) is present in the system; if 
the LDH parent was a nitrate. We can also semi-quantitatively determine the extent of 
intercalation of our anion of interest. In addition, we can obtain detailed information about 
the extent of distortion that the intercalated anions undergo by comparing the spectra of the 
original compounds with those of the intercalated LDHs. Accordingly, FTIR provided 
valuable information on the ordering of these anions in the interlayer. Thermal analysis: the 
thermal gravimetrical analysis (TGA) of LDH is used to determine the thermal stability of 
the layered materials and also the thermal stability of the intercalated anions. Elemental 
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analysis for carbon, hydrogen, and nitrogen (CHN) presents a useful technique of 
determining the percentage of the intercalated compound where LDH does not contain 
these elements. Scanning electron microscopy (SEM) and transmittance electron microscopy 
(TEM) are used to describe the structure morphology and crystal growth of LDH, and to 
provide useful information about the particle size of the LDH-composite materials. 
2.4 Properties of LDH 
LHDs display unique physical and chemical properties surprisingly close to the properties 
of clay minerals. The most interesting properties can be summarized as follows: a- High 
specific surface area, that varies from a few m2/g to ~100 m2/g. This property is useful in 
the pharmaceutical applications, gas-adsorption and purification techniques. The synthetic 
route of LDH has a great influence on its adsorption capacity (Malherbe et al., 1997).  b- 
Memory effect, which allows a reconstruction process of LDH after calcination of the 
original structure by contact with solutions containing the desired anions. The calcination-
reconstruction technique of LDH was used to prepare advanced nanocomposite materials of 
different anions. c- Anion-exchange property, this property was used to construct efficient 
bionanocomposites compounds of nucleosides (Choy et al., 2001; Lotsch et al., 2001), DNA 
(Minagawa et al., 2009; Xu et al., 2007), amino acids (Aisawa at al., 2006; Ajat et al., 2008; Chen 
et al., 2009; Reinholdt & Kirkpatrick, 2006; Wei et al., 2007) fatty acids (Nhlapo et al., 2008), 
sugars (Aisawa et al., 2003), drugs (Ladewig et al., 2009; Li et al., 2009; Tammaro et al., 2007; 
Trikeriotis & Ghanotakis, 2007; Xia et al., 2008; Zhang et al., 2009a, 2009b) and vitamins 
(Choy et al., 2004; Hwang et al., 2001; Tronto et al., 2004), through an anion-exchange 
mechanism of the interlayer anion of the original LDH. The exchange capacity of LDH was 
found to depend on the interlayer anion type. Usually LDH-NO3 nanoparticles are used in 
the exchange process where LDH has low affinity to the interlayer anion NO3 (Yahaya et al., 
2003). d- Biomedical properties, LDH possess excellent biomedical properties such as 
chemical inertness, null toxicity, biocompatibility, and antacidic and antipyretic properties. 
Consequently, they can be used as drug matrixes, drug stabilizers during storage and drug 
delivery. All in all, the previously mentioned properties of LDH raise the interest of LDH 
applications in the different biomedical fields especially the pharmaceutical one. 
3. Non-steroidal anti-inflammatory drugs (NSAIDs) 
Many drugs used for pharmacotherapy, while having a beneficial action, can also exhibit 
side-effects that may limit their clinical application. Therefore, there has been a long desire 
to achieve safe and selective delivery of drugs to target areas in the body in order to 
maximize the therapeutic potential and minimize the undesired side-effects. NSAIDs (Chart 
1) are classified base on their chemical structure including: Salicylatic acid derivatives (e.g. 
aspirin), Fenamic acid derivatives (e.g. Flufenamic acid), Acetic acid derivatives (e.g. 
Sulindac) and Propionic acid derivatives (e.g. Naproxen, Flurbiprofen, Suprofen, and 
Indoprofen). 
NSAIDs are drugs with analgesic and antipyretic effects. They also produce anti-
inflammatory effects when administrated in high doses. NSAIDs act by interfere with 
cyclooxyganase enzyme which control the production of prostaglandins responsible for 
inflammation and pain. However, prostaglandins have other vital functions, such as 
protecting the stomach from indigestion and ulcers, thus NSAIDs can have undesirable side 
effects in the gastrointestinal track and in some cases in the cardiovascular system. 
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Herein, we are going to cover the LDH nanocomposites of NSAIDs of the arylalkanoic acids 
derivatives. However most of NSAIDs are facing some administration problems such as low 
water solubility, non-target adsorption and local gastrointestinal irritation that is called 
direct contact effect. Thus, there is a need in-the-art for nanocomposite formulation 
technology to overcome the previously mentioned problems and to medicate the problems 
associated with prior conventional formulations such as milling and microcoating. 
 
 
3.1 Physicochemical properties of NSAIDs 
During drug substance development the molecules are screened in nanomolar receptor 
assays. The molecules with the best receptor binding are selected for further pre-clinical 
investigations. Already at this stage, solubility is of critical importance because it estimates 
the poorly defined drug substances and emphasizes the drug pharmacological and 
toxicological profiling. 
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When going into humans, sufficient and well characterized solubility becomes even more 
critical. The solubility or dissolution of the dose ranges in the various biophysiological 
media to which the drug substance or formulated drug substance is expected to be 
reproducible and remain unchanged for the final development and eventually marketing. It 
is well accepted today throughout the scientific community that drug substance solubility 
and especially aqueous drug substance solubility is an issue for the drug discovery as well 
as the early and late stage pharmaceutical development process and therefore needs to be 
addressed perfectly during compound design and optimization.  
Most of NSAIDs have low solubility or completely insoluble. To achieve a pharmacological 
activity of NSAIDs, the molecules must in general exhibit certain solubility in physiological 
intestinal fluids to be present in the dissolved state at the site of absorption. The aqueous 
solubility of NSAIDs is a major indicator for the drug activity in the intestinal fluids and its 
potential contribution to bioavailability issues. From literature, solubility or dissolution of 
NSAIDs can be mainly altered on two levels, through material engineering of the drug 
substance or through formulation approaches. Whatever route is taken to enhance or 
modify the solubility and/or dissolution, it needs to be a commercially viable process 
(Amidon et al., 1995; Lipinski at al., 1997; Lipinski, 2000). Furthermore, most classical 
NSAIDs have a carboxylic acid group. This acidic group can impart local gastrointestinal 
irritation through the direct contact with mucous membrane (Davies & Wallace, 1997; Emre, 
1998). Therefore, the physicochemical properties of NSAIDs should be addressed and 
controlled carefully through an advanced formulation system. 
3.2 Formulation strategies of NSAIDs 
3.2.1 Preliminary routes 
The initial drug discovery screening is typically performed with the amorphous forms of 
substances in organic solvents such as dimethylsulphoxide (Semin et al., 2005). These 
formulations of high-energy forms of the substance are sufficient for the receptor and 
efficacy screen, but neglect any solubility characteristics of the substance at this stage and 
therefore cannot allow for a relevant biopharmaceutical (i.e. absorption) assessment. For the 
continuation of the early drug discovery program, sufficient concentration of the 
amorphous or crystalline drug dissolved in aqueous test media is needed for appropriate in 
vitro and in vivo testing. When the solubility of substances in aqueous media is limited, 
simple and effective formulation strategies are required. 
3.2.2 Conventional formulations  
Particle size reduction is one of the first investigated strategies. Milling is used for particle 
size reduction; accordingly a particle size of about 200 nm has been achieved (Markus et al., 
2008). However this formulation strategy raised only the drugs surface area for rapid 
dissolution using complicated and technically challenging processes. Later on, formulations 
with solubilizing agents like cyclodextrins or micellar systems were evaluated (Mura et al., 
1995). Other systems that used solvent- or surfactant-based formulations (e.g. micro- 
emulsions) or solid dispersions with polyethylene glycol and with polyvinylpyrrolidone 
required substantial development times and might be limited due to potential excipient-
related toxicity or unwanted effects on the test system (Bettinetti & Mura, 1994; Melani et al., 
1995; Mitchell et al., 2003; Mura et al., 2001, 2003; Pignatello et al., 2002; Uekama et al., 2006). 
Upon that, drug-nanotechnology becomes a requirement.  
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Drug-delivery systems using nano- and microparticles show a clear potential for various 
diseases treatment. In view of advantages, the ability to target specific locations, the ability 
to reduce the quantity of drug that needs to be delivered to attain a particular concentration 
level in the vicinity of the target, and the ability to decrease the concentration of the drug at 
non-target sites. As a consequence, the controlled drug delivery became one of the fastest 
growing technologies of the pharmaceutical market. 
3.2.3 Clay hybrid formulations 
The strategy of using clay materials in drug formulation has been raised in the last century 
(Miyata, 1975). Several reports have evaluated the effect of the clay materials in pharmacy 
including biopharmaceutical objectives, modification of drug liberation, pharmacological 
targets to avoid or to diminish adverse effects and chemical factors. Summarizing, clays 
were found in solid forms of administration (tablets, capsules, granulates and dusts), liquid 
(suspensions and emulsions) and semisolids (ointment, pastes). In the all cases, clays 
fulfilled a series of chemical (stability and purity), physical (water texture, content, particles 
dimensions) and toxicological requirements (non-toxic, security and microbiological purity) 
(Flesken et al., 2007). In particular, the effect of clay minerals on drug solubility has received 
a great deal of intention. For example, the complexation of the analgesic indomethacin drug 
with smectite enhanced the drug-skin penetration rate and increased the drug stability as 
well as drug water solubility (Ito at al., 2001). Also, the hybridization of the poor water 
soluble itraconazole with smectites led to a remarkable improvement of the drug water 
solubility and bioavailability (Park et al., 2004). Furthermore, the intercalation of 5-
fluorouracil into montmorillonite diminished the drug side effects through its slow release 
from the hybrid materials (Lin at al., 2002).   
3.2.4 LDH nanocomposite formulations 
The work of LDH clay materials in the field of health and pharmacy has started in the last 
years. Several papers have emphasized the effect of the use of LDH nanomaterials as a drug 
carrier. Tronto et al. (Tronto at al., 2001) intercalated a variety of anions of pharmaceutical 
interest, such as salicylate, citrate, glutamate and aspartate, using two different synthesis 
methods, a direct one (coprecipitation) and an indirect one (anion exchange of 
dodecylsulfate-LDH). Bingxin et al. (Bingxin at al., 2004) showed that the release of the 
intercalated NSAID fenbufen from LDH nanocomposites is a slow process, especially in the 
case of Mg/Al intercalated materials. 
Recently, we described a new approach of improving drug solubility and absorption in the 
gastrointestinal track by using LDH nanoparticles as a drug carrier (Berber et al. 2008). In 
this work, the NSAIDs naproxen and flurbiprofen were chosen as models of poorly soluble 
drugs. Here, we study in details the effect of LDH nanocomposite structure on potential 
pharmaceutical properties of NSAIDs such as dissolution behavior, drug delivery and drug 
release. In addition, we emphasize the effect of LDH nanocomposite formulation technique 
on drug incorporation efficiency, drug preservation into the layered structure of LDH and 
drug thermal stability after the composite formation. For these investigations, we select 
some different drugs of NSAIDs such as Aspirin (ASP), Flufenamic acid (FFA), Sulindac 
(SUL), Suprofen (SUP) and Indoprofen (IND). 
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4. New experimental investigations 
4.1 Materials and drugs used  
Magnesium nitrate hexahydrate, aluminum nitrate nanohydrate and ASP (purity = 99.5, 98, 
and 99.5% respectively; Wako Pure Chemical Industries, Ltd.), FFA, SUL, NAP, FLU, SUP 
and IND high grades were purchased from Sigma Chemical Co., and used as received. All 
solutions were prepared using deionized water (18.2 MΩ/cm, produced from Milli-Q 
Grandient ZMQG000kt). 
4.2 Nanocomposite formulations of the selected drugs 
4.2.1 Synthesis of MgAl-NO3 LDH  
To a 200 mL three-necked round flask containing 30 mL of 1.0 M sodium nitrate solution 
was added dropwise a 50 mL solution of 8.538 g (0.0333 M) of magnesium nitrate 
hexahydrate and 6.249 g (0.01666 M) of aluminum nitrate nanohydrate (metal ions molar 
ratio of Mg2+/Al3+ = 2) with constant magnetic stirring. During the metal ion addition, the 
pH of the suspension was kept constant at 8.0 by adding appropriate amounts of 2.0 M 
KOH solution. The final volume of the preparation medium was augmented to 100 mL by 
deionized water. The resultant suspension was stirred at 70 ºC for 24 h under N2 flow. At 
the end of the reaction, the formed MgAl LDH material was collected by filtration (0.45 Ǎm 
Millipore membrane), washed several times with deionized water, and finally freeze-dried. 
4.2.2 Coprecipitation technique of drug-LDH 
To a 200 mL three-necked round flask, 1.0 g of the target drug was dissolved in 60 mL 
deionized water by adjusting the solution pH to 8.0 using 2.0 M KOH solution. A 30 mL 
aqueous solution containing 8.538 g Mg (NO3)2·6H2O and 0.73 g Al (NO3)3·9H2O (M2+/M3+ 
molar ratio = 2) was added dropwise with constant stirring to the drug solution. During the 
metal ion addition, the pH of the suspension was kept constant at 8.0 by adding appropriate 
amounts of 2.0 M KOH solution. The final volume of the preparation medium was 
augmented to 100 mL by deionized water. The resultant suspension was stirred at 70°C for 
24 h under N2 flow. At the end of the reaction, the formed drug-LDH material was collected 
by filtration (0.45-Ǎm Millipore membrane), washed several times by 0.1 M KOH solution 
and subsequently deionized water until a negative test was obtained for drug in the 
washing medium. A UV spectrophotometer (U-3210, Hitachi, Japan) was used to check for 
the presence of drug (ASP, FFA, SUL, NAP, FLU, SUP and IND) in the washing medium at 
235 nm, 288.0 nm, 254.0 nm, 230.5 nm, 247.0 nm, 300.4 nm and 279.0 nm respectively. 
Finally, the collected drug-LDH material was freeze-dried.  
4.2.3 Anion-exchange technique of drug-LDH 
In a 100 mL round flask was dissolved 2.0 g of drug in 100 mL of deionized water by 
adjusting the solution pH to 8.0 using 2.0 M KOH solution. To the drug solution was added 
1.0 g of NO3-LDH with constant stirring. The reaction mixture was stirred at 40 ºC for 7 
days. After the reaction completed, the drug-LDH material was collected, washed and dried 
as described above in the coprecipitation technique. 
4.2.4 Reconstruction technique of drug-LDH 
In order to prepare drug-LDH composites by reconstruction technique, the prepared NO3-
LDH sample was calcined at 500 ºC for 4.0 h under N2 flow. Depending on the memory 
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character of LDH, 1.0 g of the calcined LDH was dispersed in a 100 mL aqueous solution 
containing 1.0 g drug. The resultant suspension was stirred at 40 ºC for 48 h. The obtained 
drug-LDH was collected, washed and finally dried as described above in the coprecipitation 
technique. 
4.3 Characterization of the prepared composites 
X-ray powder diffraction patterns were recorded on a Rigaku X-ray diffractometer using 
CuKǂ radiation at ǌ=1.5405 Å. The measurement was performed in the 2θ range 1.5-70º with 
a 2θ scanning step of 0.02º, a scanning step time of 5 s, a filament intensity of 40 mA, and a 
voltage of 150 kV. Infrared spectra (KBr disk method) were recorded on a Bio-Rad FTS 
3000MX FT-IR spectrophotometer with a TGS detector in the wavenumber range of 4000-500 
cm-1 by accumulating 16 scans at 4 cm-1 resolution. Thermogravimetric analysis (TGA) was 
conducted with a Shimadzu thermogravimetric analyzer (TGA-50, TA-60WS) using a 
platinum cell with a heating rate of 10 ºC/min, under a N2 flow of 20 mL/min. The scanning 
electron micrographs (SEM) were captured by a Hitachi FE-SEMS-4700 microscope.  
5. Results and discussion 
5.1 The effect of preparation technique on drug incorporation ratio 
The amount of drug incorporated into LDH was calculated by using a UV quantitative 
method as follows. A known amount of the composite material was dissolved in 10.0 mL of 
1.0 M HCl solution. The obtained solution was diluted using a phosphate buffer of pH 7.4. 
The drug concentration was determined from the UV-absorption peak. The drug 
incorporation ratio was expressed by the percentage of drug weight intercalated into a unit 
weight of composite. The UV method was also used to check the integrity of the target drug 
after the intercalation process. 
Successfully, all the studied synthetic techniques showed drug-LDH composites; however 
the amounts of the incorporated drugs were different. The coprecipitation technique 
showed the highest loading ratio, while reconstruction method showed the lowest one as 
noted in Table 1. 
 
 ASP FFA SUL NAP FLU SUP IND 
Coprecipitation technique 53 58 45 52a 49a 49 51 
Anion exchange technique 45 42 31 43 41 40 37 
Reconstruction technique 25 19 20 23a 21a 17 18 
Table 1. The determined incorporation ratios (%), a (Berber et al., 2008) 
With no doubt, the preparation technique of LDH-composites affected the incorporation 
process of the drugs into LDH. In the coprecipitation process, the reaction medium 
contained the metals and the drug anion, accordingly LDH possesses high affinity to upload 
the drug anions and form ordered structure. In the anion exchange process, LDH is already 
constructed with its exchangeable inorganic anion, thus the exchange process is affected by 
the affinity of LDH layers to the drug charge and its size. This kind of stacking usually 
disturbs the layered structure of LDH. In the reconstruction process, the metal oxides of the 
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calcined LDH have the ability to recognize its original structure; as a consequence there is a 
high priority to reconstruct LDH layered structure of with the inorganic anions; especially 
atmospheric CO2.  
The X-ray patterns of Figure 3 confirmed the effect of the preparation technique on drug 
incorporation ratio. The absence of original LDH basal spacing peaks (pattern a) from 
pattern b and c indicated a successful synthesis of drug-LDH composites with single phase 
incorporation. The strong diffraction peaks of pattern b reflected a good crystallinity and a 
high ordered structure of drug-LDH composites prepared by coprecipitation technique. In 
the case of reconstruction technique, pattern d showed two (003) peaks style; one of low 
intensity at lower angle corresponding to the intercalated drug and the other for the CO3-
LDH with an interlayer distance 7.6Å. This means, the interlayer gallery of LDH contained 
both the drug with low content and carbonate with high content. Consequently, the method 
of drug incorporation has a profound influence on the drug incorporation ratio. 
 
 
Fig. 3. X-ray diffraction patterns of NO3-LDH (a), FFA-LDH coprecipitation (b), FFA-LDH 
anion exchange (c) and FFA-LDH reconstruction (d).  
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5.2 Nanocomposite structure of drug-LDH materials 
The scanning electron microscopy was used to investigate the nanocomposite structure of 
the prepared materials. Figure 4 displays the SEM images of the synthesized NO3-LDH 
material and FFA-LDH composites. Image a (inset) shows uniform and regular hexagonal 
platelets characteristic for LDH particles. The regularity of the LDH particles confirmed the 
good crystallinity recorded by X-ray measurement (X-ray section). The LDH particles size 
was recorded in the nanoscale. When the LDH was calcined, the hexagonal platelet structure 
disappeared (image b) as LDH particles lost their morphology. In the case of drug-LDH 
composites (images c, d and e), such LDH regular structure was demolished, and aggregates 
composed of small nanoparticles were observed. This aggregation process is probably due 
to a hydrophobic interaction of the LDH surface-adsorbed drug. The aggregates of image (e) 
were different from those of images (c) and (d). The aggregates were smaller in size and 
some regular LDH particles were observed. This difference is probably due to the applied 
preparation technique and the memory effect of LDH which recognize the original 
structure. The SEM images of the other drug-LDH materials were also recorded in the 
nanoscale and showed similar behaviors. Conclusively, the recorded SEM images confirmed 
the nanocomposite structure of synthesized drug-LDH materials. 
5.3 X-ray analysis of drug-LDH nanocomposites 
Figure 5 shows the XRD patterns of LDH, its calcined form and SUP-LDH nanocomposites 
prepared by previously mentioned synthetic methods. Pattern A indicated the formation of 
NO3 form of LDH with sharp and symmetric (00l) reflections. Using Bragg’s law (nǌ =2d sin 
θ), the basal spacing was calculated to be 8.9Å. As a result of intercalation of SUP, the basal 
d-spacing was expanded to 22.6 Å. The SUP-LDH nanocomposite interlayer distance was 
calculated by subtracting the inorganic layer thickness (4.8 Å) (Miyata, 1975) from the d003-
spacing. The determined value was 17.8 Å irrespective to the preparation technique. 
The interlayer distance of SUP-LDH was larger than SUP molecular length (12.8 Å). 
However LDH attaches its interlayer anions through an electrostatic interaction (Costantino 
et al., 1998), we speculated that SUP molecules were stacked into LDH as a monolayer of a 
staggered interdigitated arrangement through the attachment of SUP carboxyl groups with 
the LDH positive layers, as schematically drawn in Figure 6.  
Anion exchange technique (pattern c), showed a monophase drug-LDH nanocomposites. 
The NO3 anions are fully replaced by the drug anions, showing that NO3 is a good leaving 
group. The asymmetric broadening of the basal reflections (003 and 006) is typical of LDH 
composite materials with turbostratic disorder (Warren & Bodenstein, 1966; Hines et al., 
1997). This result clearly showed that the mechanism of anion-exchange disturbed the 
stacking process of the drug into the LDH layers. 
Unlike coprecipitation and anion-exchange techniques, the metal oxides resulted from the 
calcination step are subjected to a reconstruction process. The X-ray (pattern e) showed a 
biphasic nanocomposites consist of the drug-LDH (lower angle; d003 =22.6 Å) and CO3-LDH 
(higher angle; d003 =7.6 Å). The small amount of the intercalated drug indicated that LDH 
prefers to memorize its original structure (small interlayer distance) rather than 
incorporating large anions. In addition, carbonate anions seems to have a high priority to 
produce an ordered LDH structure than other anions. 
To avoid reproduction of numerous X-ray diffractions, it will suffice to describe the results 
obtained for the other drug-LDH nanocomposites. The X-ray analysis confirmed the 
formation of ASP-LDH, FFA-LDH, SUL-LDH and IND-LDH nanocomposites. The X-ray 
patterns were generally similar to those of SUP-LDH nanocomposites. The differences were 
observed in the d-spacing and the interlayer distance as schematically drawn in Figure 6. 
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Fig. 4. SEM images of NO3-LDH (a), LDH calcined (b), FFA-LDH coprecipitation (c), FFA-
LDH anion exchange (d) and FFA-LDH reconstruction (e). 
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Fig. 5. X-ray diffraction patterns of NO3-LDH (a), SUP-LDH coprecipitation (b), SUP-LDH 
anion exchange (c), calcined LDH (d) and SUP-LDH reconstruction (e).  
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Fig. 6. Schematic illustration of intercalation process of some NSAIDs.    
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Accordingly, it is concluded that drug-LDH nanocomposites are produced with a high order 
structure, single phase incorporation of the drug with a high loading ratio in the case of 
coprecipitation technique. 
5.4 Infrared spectra of drug-LDH nanocomposites 
Drug-LDH nanocomposites were further characterized by FT-IR spectroscopy to verify the 
presence of the intercalated drugs and to gather information about the nanocomposites’ 
molecular structure. For example, the infrared spectra of SUP-LDH nanocomposites which 
were prepared by different techniques are displayed in Figure 7. Figure 7a exhibited the 
characteristic bands of NO3-LDH, in particular the lattice vibration modes (ǎM-O-M, ǎM-O) at 
550, 630, and 780 cm-1 (Lin at al., 2006) and the asymmetric stretching band of the interlayer 
nitrate (ǎNO3) at 1365 cm-1 as well as the vibration modes of the hydroxyl groups of LDH 
layers; bending at 960 cm-1, deformation at 1610 cm-1 and stretching at 3440 cm-1 
(Olanrewaju et al., 2000).The FT-IR spectrum of SUP (Figure 7b) showed complex features 
below 1520 cm-1, which can be attributed to the bending and stretching of aromatic rings, 
carbon-carbon, carbon-sulfur, and carbon-oxygen bonds. The stretching vibration band of 
COOH group was detected at 1740 cm-1. The weak stretching vibration modes of SUP alkyl 
groups (ǎC-H) were detected between 3060 and 2870 cm-1. 
As a result of intercalation of SUP into LDH, new bands are emerged such as symmetric and 
asymmetric modes of COO- at 1560 and 1670 cm-1, respectively, besides the characteristic 
bands of SUP and LDH. The intensities of the emerged bands suggested a dependence on 
the amount of the intercalated drug. The bands were sharp in the case of coprecipitation and 
anion exchange techniques, respectively, indicating a high loading ratio of the drug into the 
LDH gallery. The lack of the inorganic anions in the interlayer indicated the formation of 
monophase drug-LDH nanocomposites. On the other side, the reconstruction technique 
(spectrum e) showed the valence vibration of carbonate anion at 1410 cm-1 (Del Arco et al., 
1993) beside the characteristic bands of SUP, confirming the formation of biphasic 
nanocomposites. The presence of carbonate band in spite of the precautions taken during 
the preparation process indicates the high selectivity of LDH for carbonate anion (Miyata, 
1980). The weak bands of the drug reflected its low interlayer contribution. In conclusion, 
the molecular structure information of drug-LDH nanocomposites indicated that drug 
molecules are intercalated into LDH gallery with different ratios depending on loading 
technique and are combined with LDH layers through electrostatic interactions. 
5.5 Pharmaceutical properties of NSAIDs and their LDH nanocomposites 
5.5.1 Drug thermal stability 
An important pharmaceutical use of LDH compounds could be drug stabilizing during 
storage. The active ingredient was protected by the laminar structure. In the case of the 
used drugs, photodecarboxylation was prevented because of the interaction of the 
carboxylate groups of NSAIDs and the positive layer charges. During storage, the layers 
of LDH supply a well-defined and relatively hydrophobic microenvironment for these 
guest molecules, accordingly LDH controlled the guest hydrolysis and photoreactivity 
(Cavani et al., 1991; Costantino & Nocchetti, 2001). Figure 8 shows the TGA and 
differential thermal analysis curves of LDH, SUP, and SUP-LDH prepared by co-
precipitation technique. 
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Fig. 7. Infrared spectra of LDH-NO3 (a), SUP drug (b), SUP-LDH prepared by 
coprecipitation technique (c), SUP-LDH prepared by anion-exchange technique (d), and 
SUP-LDH prepared by reconstruction technique (e). 
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Fig. 8. Thermogravimetric analysis and differential curves of LDH-NO3 (a), SUP drug (b), 
and SUP-LDH prepared by coprecipitation technique (c). 
In the case of LDH (Figure 8a), the weight loss was observed to proceed mainly in three 
steps: ~11.8% starting from 90 °C, reaching maximum at 130 °C and ended at 170 ºC (the loss 
of the physically adsorbed water molecules) (Darder et al., 2005), ~4% from 170 to 270 ºC 
(the loss of the interlayer water molecules), and ~39% from 270 to 620 ºC (the 
dehydroxylation process and the decomposition of the interlayer anions) (Lopez et al., 1997). 
The formation of MgO and MgAl2O4 oxides was observed in the TGA residue by measuring 
X-ray diffraction (Figure 9). The resultant oxides were in agreement with previous literature 
data (Labajos et al., 1992). 
After the intercalation of SUP into LDH, the TGA curve (Figure 8c) was significantly 
changed. The amount of interlayer water was decreased, probably due to the hydrophobic 
nature of the intercalated SUP. The overall weight loss was increased from 55% to 67% in 
the final stage. The onset temperature of drug decomposition shifted to a higher value (from 
190 °C to 245 °C). Similar changes were also observed in the TGA curves of the samples 
prepared by anion-exchange and reconstruction techniques. The differences were observed 
in the reduced weight loss which was related to the small content of the intercalated drug 
and the presence of carbonate as an interlayer component beside the drug in the case of 
reconstruction techniques. Accordingly, the stability of SUP was promoted against the 
thermal decomposition after the LDH nanocomposite formulation. 
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Fig. 9. X-ray pattern of TGA residue of LDH-NO3 
5.5.2 Drug delivery of NSAIDs and their LDH nanocomposites 
The dissolution experiments of the pure drugs and drug-LDH nanocomposites was 
monitored in the following buffer mediums: buffer A as a simulated stomach solution (a 100 
mL solution mixture of 100.0 mM HCl and 100.0 mM KCl; a few drops of 10.0 mM HCl 
solution was used to adjust the solution pH at 2.0), buffer B as a simulated duodenum 
solution (a 100 mL solution mixture of 100.0 mM NaHCO3 and 100.0 mg NaCl; a few drops 
of 50.0 mM HCl solution was used to adjust the solution pH at 6.0), and buffer C as a 
simulated small intestine solution (a 100 mL solution mixture of 100.0 mM NaHCO3 and 
100.0 mg NaCl; a few drops of 50.0 mM HCl solution was used to adjust the solution pH at 
8.0). The anionic buffer composition was defined on the basis of literature data (Vatier et al., 
1992; White, 1980). By considering both of the usual daily doses of the selected drugs and 
the drug ratio incorporated into LDH, the release experiments were conducted with 
sufficient amounts of drugs-LDH nanocomposites to study the effect of LDH on drug-
release properties and to ensure a good therapeutic effect. Consequently, the release 
experiments were performed as follows: In a round-bottom flask, a sample of 100.0 mg of 
drug or 200.0 mg of drug-LDH nanocomposite was dispersed in 100 mL of buffer solution, 
which was maintained at 36.8±0.1°C with constant agitation of 80 rpm. At appropriate time 
intervals, a 1.0 mL sample solution was withdrawn from the release medium and filtered by 
using a 0.45 Ǎm Millipore filter unit to remove the insoluble particles. The filtrate was 
diluted and assayed for UV measurement. The removed aliquot was immediately 
replenished by the same volume of the used buffer, which was equilibrated at the same 
reaction temperature. The dissolution experiment of each sample in each buffer was 
performed in duplicates (Berber et al., 2010). 
Figure 10 (upper panel) shows the solubility of SUP drug powder at the different mediums. 
The solubility was very small in buffer A (~ 6%), due to the acidic character of SUP. The 
drug was completely dissolved during 30 min (buffer B) and 25 min (buffer C), due to 
deprotonation of carboxylic acid group at high pH(s). These observations indicate the 
uncontrollable dissolution of SUP in the gastrointestinal tract after administration. Figure 10 
(lower panel) shows the release of SUP from LDH nanocomposite prepared by 
coprecipitation technique. Significant change in the amount of drug dissolved was observed 
with time progress. Around 32%, 53% and 71% was released in a controlled process during 
www.intechopen.com
  
Advances in Nanocomposite Technology 
 
354 
12 h in buffer A, B and C, respectively. The release of the intercalated SUP depended on 
both medium anionic species and LDH nanocomposite properties. However, LDH possesses 
an anion exchange selectivity for carbonate than chloride (Kaneyoshi & Jones, 1998; Miyata, 
1983; Wang et al., 2009), the release of the drug in buffers B and C was higher than in buffer 
A. Additionally, the layered molecular structure of LDH limited the intercalation of the 
drug in two-dimensional directions. Such kind of stacking process prevents the 
crystallization of the drug into the gallery of LDH. As a consequence, the drug was released 
in an amorphous form suitable for dissolution.  
The release studies of the other drugs LDH nanocomposites showed similar behaviors and 
changes as SUP did before and after LDH nanocomposite formation. The differences were 
observed only in the amounts released and releasing times. The improved release properties 
of the other drug-LDH nanocomposites were also related to the medium anionic species and 
LDH nanocomposite properties. 
The question arises now: How LDH supports a controlled release process of the intercalated 
drug? With no doubt the exchange mechanism is the key answer. The phase boundary 
formed between the internal zone (drug-LDH; large d-spacing) and the external zone 
(exchanged LDH; small d-spacing) during the medium anion exchange process decreased 
the amount of drug released with time progress, consequently a controlled behavior was 
obtained (Kaneyoshi & Jones, 1998). At this stage and from the observations of release data, 
we can say that LDH nanocomposite platform enhanced the solubility of NSAIDs and 
diminished the drug high local concentration through a controlled release process. 
Furthermore, LDH material lowered the direct gastrolesivity of the NSAIDs drugs through 
its barrier properties. 
 
 
Fig. 10. Release profile of pure SUP (upper panel) and SUP-LDH nanocomposites (lower 
panel) in buffer A (◊), buffer B (■) and buffer C (∆). panel 
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6. Prospects for the future of LDH 
With no doubt, one of the most important advances of science and technology is the birth of 
nanocomposites materials. From the many significant research achievements in the past 
decade and the many potential practical applications, it is assumed that the prospects for 
nanocomposite research are very bright indeed. From commercial, industrial, and scientific 
point of views, clay nanocomposites are of particular interest due to their previously 
discussed properties. At present, even though a great deal of work on LDH materials has 
been carried out, still more remains to be done in order to exploit completely their potential 
applications.  
Regarding information required for developing LDH nanocomposite science, three specific 
areas of research seem particularly important. The first is the optimization of present 
synthetic techniques or the innovation of new methodologies; however uniform LDH 
nanoparticles are not synthesized yet, and literature data strongly emphasized the effect of 
LDH nanoparticle size and its distribution ratio on the applications of LDH. In this regard, 
high quality basic research should be the foundation of our discipline. The directions of the 
basic science of LDH nanocomposites should remain open, driven by the flow of the 
scientific inquiry to prepare more advanced nanocomposites. Another area of focus is the 
establishment of new tools for the characterization of nanocomposites. It is well known that 
X-ray analysis is the only standard technique for the identification of clay nanocomposites. 
Sometimes during the analysis, peaks related to specific groups are identified by using IR 
spectroscopy but not by X-ray spectroscopy. Hence, much more research should be directed 
towards the innovation of new sensitive measurement techniques. Still another direction to 
consider for future LDH nanocomposite research might be the stacking mechanism of the 
bioactive compounds into the layers during the nanocomposite formation. Some 
nanocomposites are suggested to be produced in a monolayer stacking process while others 
are formed through a bilayer stacking process. In fact, the complete understanding of the 
interaction mechanism between the bioactive anions and the inorganic layers in addition to 
the exfoliation mechanism of the layers during the nanocomposite formation are important 
issues of research and will help in the preparation of more advanced nanocomposites. 
Because we believe that the future of the nano-dimensional LDHs carries new innovations 
of utilization in the different fields, professional organizations such as high ranked 
universities and academic institutes are encouraged to sponsor and to focus on the LDH 
nanocomposite research. 
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